Grzegorz Nowakowski, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Daiichi Sankyo, Inc.
    Date added:
    09/29/2023
    Date updated:
    09/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Karyopharm Therapeutics
    Date added:
    09/29/2023
    Date updated:
    09/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Kite Pharma, Inc.
    Date added:
    09/29/2023
    Date updated:
    09/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Karyopharm Therapeutics
    Date added:
    09/29/2023
    Date updated:
    09/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Bantam Pharmaceutical, LLC
    Date added:
    09/29/2023
    Date updated:
    09/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Zai Laboratory
    Date added:
    09/29/2023
    Date updated:
    09/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Kymera Therapeutics
    Date added:
    09/29/2023
    Date updated:
    09/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    TG Therapeutics, Inc
    Date added:
    09/29/2023
    Date updated:
    09/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Blueprint Medicines Corporation
    Date added:
    09/29/2023
    Date updated:
    09/29/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Constellation Pharmaceuticals
    Date added:
    09/29/2023
    Date updated:
    09/29/2023

Pages

Return to Bridging Hematologic Cancer Disparities: A Path to Equity